- 86 -

6 Literaturverzeichnis
Aydin C., Ulnap H. R., Baloglu A., Inci A. G., Yigit S., Yavuzcan A. (2008) Axillary lymph node metastasis from serous ovarian cancer: a case report and review of the literature Arch Gynecol Obstet. 2008 May 10. (Epub ahead of print) Baekelandt M., Kristensen G. B., Trope C. G., Nesland J. M., Holm R. (1999) Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer. Anticancer Res. 19: Bartlett J.M., Langdon S. P., Simpson B. J., Stewart M., Katsaros D., Sismondi P., Love S., Scott W. N., Williams A. R., Lessells A. M., Macleod K. G., Smyth J. F., Miller W. R. (1996) The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer Br J Cancer. 73: 301306 Baselga J., Albanell J., Molina M. A., Arribas J. (2001) Mechanism of action of trastuzumab and scientific update Semin Oncol. 28 (Suppl. 16): 4-11 Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., Soper J. T., Dodge R., Clarke-Pearson D. L., Marks P., McKenzie S., Yin S., Bast R. C., Jr. (1990) Overexpression of HER-2/neu Is Associated with Poor Survival in Advanced Epithelial Ovarian Cancer Canc Res. 50: 4087-4091 Bookman M. A., Darcy K. M., Clarke-Pearson D., Boothby R. A., Horowitz I. R. (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent of refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group J Clin Oncol. 21: 283-290 Brustmann H. (2004) Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II and prognosis Gynecol Oncol. 95: 16-22 Brustmann H. et Naude S. (2002) Expression of topoisomerase IIalpha, Ki-67, proliferating cell nuclear antigen, p53, and argyrophilic nucleolar organizer regions in vulvar squamous lesions Gynecol Oncol. 86: 192-199 - 87 -
Bull Phelps S. L., Schorge J. O., Peyton M. J., Shigematsu H., Xiang L.-L., Miller D. S., Lea J. S. (2008) Implications of EGFR inhibition in ovarian cancer cell proliferation Gynecol Oncol. 109 (3): 411-417 Cappuzzo F., Hirsch F. R., Rossi E., Bartolini S., Ceresoli G. L., Bemis L., Haney J., Witta S., Danenberg K., Domenichini I., Ludovini V., Magrini E., Gregorc V., Doglioni C., Sidoni A., Tonato M., Franklin W. A., Crino L., Bunn P. A. Jr., Varella-Garcia M. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst. 97 (9): 643-655 Cerciello F., Riesterer O., Sherweif M., Odermatt B., Ciernik F. I. (2007) Is EGFR a moving target during radiotherapy of carcinoma of the uterine cervix? Gynecol Oncol. 106: 394-399 Chekerov R., Klaman I., Zafrakas M., Knsgen D., Mustea A., Petschke B., Lichtenegger W., Sehouli J., Dahl E. (2006) Altered Expression Pattern of Topoisomerase II in Ovarian Tumor Epithelial and Stromal Cells after Platinum-Based Chemotherapy Neoplasia. 8 (1): 38-45 Chen Y., Wu P.-C., Lang J.-H., Ge W.-J., Hartge P., Brinton L. A. (1992) Risk Factors for Epithelial Ovarian Cancer in Beijing, China Int J Epidemiol. 21: 23-29 Costa M. J., Hansen Ch. L., Holden J. A., Guinee Jr. D. (2000) Topoisomerase II: Prognostic Predictor and Cell Cycle Marker in Surface Epithelial Neoplasms of the Ovary and Peritoneum Int J Gynecol Pathol. 19: 248-257 Dako, Denmark (2006) Pathology. EGFR pharmDxTM. Interpretation Manual Dako, Denmark (2007) TOP2A FISH pharmDxTM Kit. Code K5333 3. Ausgabe DakoCytomation, USA (2002) HercepTest. A Manual for Interpretation. Targeted Therapies Require Targeted Diagnostics DakoCytomation, Denmark (2005) Monoclonal Mouse Anti-Human Topoisomerase II Clone Ki-S1

15. 16.

- 88 -
De Potter C. R., Quatacker J., Maertens G., Van Daele S., Pauwels C., Verhofstede C., Eechaute W., Roels H. (1989) The subcellular localization of the neu protein in human normal and neoplastic cells Int J Cancer. 44 (6): 969-974 Depowski P. L., Rosenthal S. I., Brien T. P., Stylos S., Johnson R. L., Ross J. S. (2000) Topoisomerase II Expression in Breast Cancer: Correlation with Outcome Variables Mod Pathol. 13 (5): 542-547 Deutsche Krebsgesellschaft e. V.(2007) Krebsentstehung was ist Krebs? Deutsche Krebsgesellschaft e. V. (2007) Krebshufigkeit die aktuellen Zahlen Di Leo A., Gancberg D., Larismont D., Tanner M., Jarvinen T., Rouas G., Dolci S., Leroy J.-Y., Paesmans M., Isola J., Piccart M. J. (2002) HER-2 Amplification and Topoisomerase II Gene Aberrations as Predictive Markers in Node-positive Breast Cancer Patients Randomly Treated Either with an Anthracycline-based Therapy or with Cyclophosphamide, Methotrexate and 5-Fluorouracil Clin Canc Res. 8: 1107-1116 Di Leo A., Larismont D., Gancberg D., Jarvinen T., Beauduin M., Vindevoghel A., Michel J., Focan C. H., Ries F., Gobert P. H., ClosonDejardin M. T., Dolci S., Rouas G., Paesmans M., Lobelle J. P., Isola J., Piccart M. J. (2001) HER-2 and topoisomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide Ann Oncol. 12 (8): 1081-1089 Dinh P., Harnett P., Piccart-Gebhart M. J., Awada A. (2008) New therapies for ovarian cancer: Cytotoxics and molecularly targeted agents Crit Rev Oncol Hematol. 67 (2): 103-112 Downs-Kelly E., Yoder B. J., Stoler M., Tubbs R. R., Skacel M., Grogan T., Roche P., Hicks D. G. (2005) The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a flourescent in situ hybridization, immunohistochemical and isotopic mRNA in situ hybridization study Am J Surg Pathol. 29 (9): 1221-1227 Fajac A., Bernard J., Lhomme C., Rey A., Duvillard P., Rochard F., Bernaudin J. F., Riou F. (1995) C-erbB 2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis Int J Cancer. 64 (2): 146-151 - 89 -

21. 22. 23.

Faratian D. and Bartlett J. (2008) Predictive markers in breast cancer the future Histopathology 52: 91-98 Fritz P., Cabrera C. M., Dippon J., Gerteis A., Simon W., Aulitzky W. E., van der Kuip H. (2005) C-erbB2 and topoisomerase II protein expression independently predict poor survival in primary human breast cancer: a retrospective study Breast Cancer Res. 7 (3): R374-R384 Future Oncology: Mechanisms in Malignancy. The Epidermal Growth Factor Receptor (EGFR) Pathway in Cancer. Part I Ligands, Receptors and Downstream Effectors A New Medicine Publication (2007) Siafaca K., Tankosic T., Pestonjamasp V. (Eds.) New Medicine Inc., Vol. 8, Number 11/12: 1922-1956 Giaccone G., Gazdar A. F., Beck H., Zunino F., Capranico G. (1992) Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression Cancer Res. 52 (7): 1666-1674 Goff B. A., Muntz H. G., Greer B. E., Tamimi H. K., Gown A. M. (1998) Oncogene expression: long-term compared with short-term survival in patients with advanced epithelial ovarian cancer. Obstet Gynecol. 92 (1): 88-93 Goldstein N. S. and Armin M. (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Commmittee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system Cancer. 92: 1331 Hannemann J., Kristel P., van Tinteren H., Bontenbal M., van Hoesel Q. G. C. M., Smit W. M., Nooij M. A., Voest E. E., van der Wall E., Hupperets P., de Vries E. G. E., Rodenhuis S., van de Vijver M. J. (2006) Molecular subtypes of breast cancer and amplification of topoisomerase IIa: predictive role in dose intensive adjuvant chemotherapy Br J Cancer. 95: 1334-1341 Hellstrm I., Goodman G., Pullman J., Yang Y., Hellstrm K. E. (2001) Overexpression of HER-2 in Ovarian Carcinomas Canc Res. 61: 2420-2423 Hengstler J. G., Lange J., Kett A., Dornhfer N., Meinert R., Arand M., Knapstein P. G., Becker R., Oesch F., Tanner B. (1999) Contribution of c-erbB-2 and Topoisomerase II to Chemoresistance in Ovarian Cancer Canc Res. 59: 3206-3214

- 90 -

Hicks D. G., Yoder B. J., Pettay J., Swain E., Tarr S., Hartke M., Skacel M., Crowe J. P., Budd G. T., Tubbs R. R. (2005) The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study Hum Pathol. 36 (4): 348-356 Interdisziplinre S2k-Leitlinie fr die Diagnostik und Therapie maligner Ovarialtumoren (2006, berarbeitet 2007) Herausgegeben von der Kommission Ovar der Arbeitsgemeinschaft Gynkologische Onkologie e.V. in der Deutschen Gesellschaft fr Gynkologie und Geburtshilfe e.V. sowie in der Deutschen Krebsgesellschaft e.V. 1. Auflage, W. Zuckschwerdt Verlag Mnchen Wien New York Isaacs R. J., Davies S. J., Sandri M. I., Redwood C., Wells N. J., Hickson I. D. (1998) Physiologic regulation of eukaryotic topoisomerase II Biochem Biophys Acta. 1400: 121-137 Isaacs R. J., Harris A. L., Hickson I. D. (1996) Regulation of the human topoisomerase IIalpha gene promoter in confluencearrested cells J Biol Chem. 271: 16741-16747 Isola J. J., Tanner M., Holli K., Joensuu H. (2000) Amplification of topoisomerase II is a strong predictor of response to epirubicin-based chemotherapy in HER-2/neu positive matastatic breast cancer Breast Cancer Res Treat. 68: 31 Jacobs T., Gown A., Yaziji H., Barnes M., Schnitt S. (1999) Her-2/neu protein expression in breast cancer immunhistochemistry. A study of interlaboratory agreement Am J Clin Pathol 113 (2): 251-258 evaluated by
Jrvinen T. A. H., Tanner M., Rantanen V., Brlund M., Borg., Grnman S., Isola J. (2000) Amplification and Deletion of Topoisomerase IIa Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast Cancer Am J Pathol. 156: 839-847 Kaern J., Aghmesheh M., Nesland J. M., Danielsen H. E., Sandstad B., Friedlander M., Trop C. (2005) Prognostic factors in ovarian carcinomas stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? Int J Gynecol Cancer. 15 (6): 1014-1022 Kamura T., Jeon J. D. (2002) Lymph node metastasis in a gynecologic malignancy Yonsei Med J. 43 : 783-791

- 91 -

Knoop A. S., Knudsen H., Balslev E., Rasmussen B. B., Overgaard J., Nielsen K. V., Schonau A., Gunnarsdttir K., Olsen K. E., Mouridsen H., Ejlertsen B. (2005) Retrospective Analysis of Topoisomerse IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group J Clin Oncol. 23: 7483-7490 Kury F. D., Schneeberger C., Sliutz G., Kubista E., Salzer H., Medl M., Leodolter S., Swoboda H., Zeillinger R., Spona J. (1990) Determination of HER2/neu amplification end expression in tumour tissue and cultured cells using a simple phenol free method for nucleic acid isolation Oncogene. 5 (9): 1403-1408 Lafky J. M., Wilken J. A., Baron A. T., Maihle N. J. (2008) Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer Biochem Biophys Acta. 1785: 232-265 Landis S. H., Murray T., Bolden S., Wingo P. A. (1999) Cancer Statistics, 1999 CA Cancer J Clin. 49: 8-33 Lassus H., Sihto H., Leminen A., Joensuu H., Isola J., Nupponen N. N., Butzow R. (2006) Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma J Mol Med. 84: 671-681 Ma Y., Lespagnard L., Durbecq V., Paesmans M., Desmedt C., GomezGaldon M., Veys I., Cardoso F., Sotiriou C., Di Leo A., Piccart M. J., Larismont D. (2005) Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice Clin Cancer Res. 11 (12): 4393-4399 Mano M. S., Awada A., Di Leo A., Durbeq V., Paesmans M., Cardoso F., Larsimont D., Piccart M. (2004) Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma Gynecol Oncol. 92: 887-895 Mayr D., Kanitz V., Amann G., Engel J., Burges A., Lhrs U., Diebold J. (2005) HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays Histopathology. 48: 149-156

- 92 -

McKeage K. and Perry C. M. (2002) Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2 Drugs. 62: 209-243 Meden H., Marx D., Raab T., Kron M., Schauer A., Kuhn W. (1995) EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value J Obstet Gynaecol. 21: 167178 Meden H., Marx D., Roegglen T., Schauer A., Kuhn W. (1998) Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer Int J Gynecol Pathol. 17 (1): 61-65 Miettinen H. E., Jarvinen T. A., Kellner U., Kauraniemi P., Parwaresch R. Rantala I., Kalimo H., Paljarvi L., Isola J., Haapasalo H. (2000) High topoisomerase IIalpha expression associates with high proliferation rate and poor prognosis in oligodendrogliomas Neuropathol Appl Neurobiol. 26: 504-512 Mueller R. E., Parkes R. K., Andrulis I., OMalley F. P. (2004) Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples Genes Chromosomes Cancer. 39 (4): 288-297 Nielsen K. V., Ejlertsen B., Mller S., Jrgensen J. T. Knoop A., Knudsen H., Mouridsen H. T. (2008) The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D Acta Oncol. 47 (4): 725-734 Olsen C. M., Cnossen J., Green A. C., Webb P. M. (2007) Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumors Eur J Gynaecol Oncol. 28 (5): 376-380 Olsen K. E., Knudsen H., Rasmussen B. B., Balsley E., Knoop A., Ejlertsen B., Nielsen K. V., Schnau A., Overgaard J.; Danish Breast Cancer Cooperative Group (2004) Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cacer investigated by new FISH probes Acta Oncol 43(1): 35-42 Pauletti G., Dandekar S., Rong H., Ramos L., Peng H., Sheshadri R., Slamon D. (2000) Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunhistochemistry J Clin Onco. 18 (21): 3651-3664

- 93 -

Pike M. C., Pearce C. L., Peters R., Cozen W., Wan P., Wu A. H. (2004) Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study Fertil Steril. 82 (1): 186-195 Press M. F., Slamon D. J., Flom K. J., Park J., Zhou J.-Y., Bernstein L. (2002) Evaluation of HER-2/neu Gene Amplifikation and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens J Clin Oncol. 20: 3095-3105 Protopapas A., Diakomanolis E., Bamias A., Milingos S., Markaki S., Papadimitriou C., Dimopoulos A. M., Michalas S. (2004) The prognostic significance of the immunohistochemical expression of p53, bcl2, c-erbB2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclo-phosphamide of paclitaxel chemotherapy Eur J Gynaecol Oncol. 25 (2): 225-229 Psyrri A., Kassar M., Yu Z., Bamias A., Weinberger P. M., Markakis S., Kowalski D., Camp R. L., Rimm D. L., Dimopoulos M. A. (2005) Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer Clin Cancer Res. 11: 8637-8643 Raspollini M. R., Amunni G., Villanucci A., Castiglione F., Rossi DeglInnocenti D., Baroni G., Paglierani M., Taddei G. L. (2006) HER-2/neu and bcl-2 in Ovarian Carcinoma: Clinicopathologic, Immunohistochemical, and Molecular Study in Patients With Shorter and Longer Survival Appl Immunohistochem Mol Morphol. 14: 181-186 Reddy J. C., Reimann J. D., Anderson S. M., Klein P. M. (2006) Concordance between central and local laboratory HER2 testing from a community-based clinical study Clin Breast Cancer. 7 (2): 153-157 Reese D. and Slamon D. (1997) HER-2/neu signal transduction in human breast and ovarian cancer Stem. 15 (1):1-8 Remmele W. (Hrsg.), Bssler R., Bcker W., Dallenbach-Hellweg G., Dietel M., Harms D. Klppel G., Mntefering H., Poldleck J., Saeger W., Schmid K. W., Schmidt D., Vogel M. (1997) Pathologie Bd. 4. Weibliches Genitale; Mamma; Pathologie der Schwangerschaft, der Plazenta und des Neugeborenen; Infektionskrankheiten des Fetus und des Neugeborenen; Tumoren des Kindesalters; Endokrine Organe (S. 90-123) 2., neubearbeitete Auflage 1997 Springer-Verlag Berlin Heidelberg New York - 94 -
Remmele W. and Stegner H., E. (1987) Recommendation for uniform definition of a immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue Pathologe. 8 (3): 138-140 Robert Koch-Institut (Hrsg.) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (Hrsg.), Berlin (2008) Krebs in Deutschland 2003-2004 Hufigkeit und Trends 6. berarbeitete Auflage Ross J. S., Yang F., Kallakury B. V., Sheehan C. E., Ambros R. A., Muraca P. J. (1999) HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary Am J Clin Pathol. 111 (3): 311-316 Rubin S. C., Finstad C. L., Wong G. Y., Almadrones L., Plante M., Lloyd K. O. (1993) Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis Am J Obstet Gynecol. 168 (1 Pt. 1): 162-169 Sassen A., Rochon J., Wild P., Hartmann A., Hofstaedter F., Schwarz S., Brockhoff G. (2008) Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cacer patients Breast Cacer Res. 10 (1): R2 Schilder F. J., Sill M. W., Chen X., Darcy K. M., Decesare S. L., Lewandowski G., Lee R. B., Arciero C. A., Wu H., Godwin A. K. (2005) Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study Clin Cancer Res. 11: 5539-5548 Schoenberg Fejzo M., Slamon D. J. (2001) Technical Advance. Frozen Tumor Tissue Microarray Technology for Analysis of Tumor RNA, DNA, and Proteins Am J Pathol. 159 (5): 1645-1650 Scully R. E. (1999) Histological typing of ovarian tumors. WHO International Histological Classification of Tumours 2nd ed. Springer, Berlin Heidelberg New York. Scully R. E., Henson D. E., Nielsen M. L., Ruby S. G. (1996) Practice protocol for the examination of specimens removed from patients with ovarian tumors. A basis for checklists Cancer. 78:927-940 - 95 -

Silva E. G., Gershenson D. M. (1998) Standardized histologic grading of epithelial ovarian cancer: elusive after all these years Gynecol Oncol. 70:1 Silverberg S. G. (2000) Histopathologic grading of ovarian carcinoma: a review and proposal Int J Gynecol Pathol. 19:7-15 Slamon D., Godolphin W., Jones L., Holt J., Wong S., Keith D., Levin W., Stuart S., Udove J., Ullrich A., Press M. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science. 244: 707-712 Sng J. H., Heaton V. J., Bell M., Maini P., Austin C. A., Fisher L. M. (1999) Molecular cloning and characterization of the human topoisomerase IIalpha and IIbeta genes: evidence for isoform evolution through gene duplication Biochem Biophys Acta. 1444: 395-406 Stadlmann S., Gueth U., Reiser U., Diener P.-A., Zeimet A. G., Wight E., Mirlacher M., Sauter G., Mihatsch M. J., Singer G. (2006) Epithelial growth factor receptor status in primary and recurrent ovarian cancer Modern Pathology. 9: 607-610 Statistisches Bundesamt (2008) Todesursachenstatistik in Deutschland Fachserie 12, Reihe 4, 1-114 Surowiak P., Materna V., Kaplenko I., Spaczynski M., Dietel M., Lage H., Zabel M. (2006) Topoisomerase 1A, Her/2neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples Histol Histopathol. 21: 713-720 Tammela J. et Odunsi K. (2004) Gene expression and prognostic significance in ovarian cancer Minerva Ginecol. 56 (6): 495-502 Review Tanner M., Jrvinen P., Isola J. (2001) Amplification of HER-2/neu and topoisomerase II in primary and metastatic breast cancer Canc Res. 61: 5345-5348 Tavassoli F. A., Devilee P. (Eds.) (2003) World Health Organization Classification of Tumours. Pathology and Genetics of the Breast and Female Genital Organs S. 114-116 IARC Press: Lyon 2003

- 96 -

Trastour C., Rahili A., Schumacker Ch., Effi A. B., Bernard J.-L. (2004) Hematogenous rectal metastasis 20 years after removal of epithelial ovarian cancer Gynecol Oncol. 94: 584-588 Troxell M. L., Bangs Ch., Lawce H. J., Galperin I. B., Baiyee D., West R. B., Olson S. B., Cherry A. M. (2006) Evaluation of Her-2/neu Status in Carcinomas With Amplified Chromosome 17 Centromere Locus Am J Clin Pathol. 126: 709-716 Tsai-Pflugfelder M., Liu A. A., Tewey K. M., Whang-Peng J., Knutsen T. (1988) Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22 Proc Natl Acad Sci USA. 85: 7177-7181 Tsiambas E., Alexopoulou D., Lambropoulou S., Gerontopoulos K., Karakitsos P., Karameris A. (2006) Targeting topoisomerase II in endometrial adenocarcinoma: a combined chromogenic in situ hybridization and immunohistochemistry study based on tissue microarrays Int J Gynecol Cancer. 16: 1424-1431 Tumorzentrum Sdost-Niedersachsen (2006) Leitlinie: Ovarialkarzinom Liebrich 02/2006 Tung K.-H., Wilkens L. R., Wu A. H., McDuffie K., Nomura A. M. Y., Kolonel L. N., Terada K. Y., Goodman M. T. (2005) Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis Am J Epidemiol. 161 (4): 321-329 Ullrich A., Schlessinger J. (1990) Signal transduction by receptors with tyrosine kinase activity Cell. 61: 203-212 Van der Burg M. E., Henzen-Logmans S. C., Foekens J. A., Berns E. M., Rodenburg C. J., van Putten W. L., Klijn J. G. (1993) The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study Eur J Cancer. 29A: 19511957 Van der Zee A. G., De Vries E. G., Hollema H., Kaye S. B., Brown R., Keith W. N. (1994) Molecular analysis of the topoisomerase II alpha gene and its expression in human ovarian cancer Ann Oncol. 5 (1): 75-81